Zevra Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Zevra Therapeutics, Inc. Overview

Zevra Therapeutics is a commercial-stage rare disease pharmaceutical company focused on developing life-changing therapeutics for patients with limited treatment options. The company leverages its proprietary Ligand Activated Technology platform to address unmet medical needs in rare diseases including Niemann-Pick disease type C, urea cycle disorders, and rare sleep disorders.

Strategic Profile

Zevra has positioned itself as a data-driven developer and commercializer of rare disease therapies through strategic partnerships and acquisitions, most notably the Acer Therapeutics acquisition in November 2023. The company demonstrates commitment to bringing therapies to market through expanded access programs and collaborations with advocacy groups and thought leaders in the rare disease community.

Competitive Landscape

Zevra competes within the broader rare disease therapeutics sector against specialized biotech companies and larger pharmaceutical firms with rare disease divisions. Key competitive factors include regulatory approval status, clinical efficacy data, commercial infrastructure, and patient access programs. The company's focus on orphan indications with limited treatment options provides some competitive insulation compared to larger therapeutic categories.

Industry Context

Zevra Therapeutics, Inc. operates in Rare Disease Pharmaceuticals & Biotechnology.

Key facts

Founded: 2006 · Headquarters: Celebration, Florida, US · Revenue: $84.4M · Market cap: $573M